Cordyceps Sunshine Biotech Holdings Co., Ltd. RAJAF
Annual
Quarterly
FY2025 · ended Dec 31, 2025 · Revenue $1.25M, -0.6% YoY · Filed May 15, 2026
Cordyceps Sunshine Biotech Holdings Co., Ltd. (RAJAF) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.2 million and a net loss of $154,822. As of Dec 31, 2025 it held $3,199 in cash and investments and $13,173 in total debt.
Revenue
$1.25M
-0.6% vs prior year
Net income
$-154,822
+31.6% vs prior year
Operating cash flow
$-35,845
-111.5% vs prior year
Free cash flow
$-37,231
-192.5% vs prior year
EPS
$0.00
Dividend per share
None
Shares outstanding
111.12M
+0.0% vs prior year
Net cash
$-9,974
FY 2025
Operating margin
-11.3%
FY 2025
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- RAJAF (OTC)
- Fiscal year ends
- December 31
- Headquarters
- Taipei City
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1885680
- Former names
- Cordyceps Sunshine Biotech Holdings Co., Ltd. (until Jun 25, 2026)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
- Aurora Cannabis Inc ACB
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
|---|---|---|---|---|
| Revenue | $1.2M | $1.3M | $882,533 | $53,304 |
| Operating income | -$141,128 | -$183,913 | $227,833 | -$415,121 |
| Net income | -$154,822 | -$226,258 | $751,609 | -$720,093 |
| Diluted EPS | $0.00 | $0.00 | $0.01 | -$0.01 |
| Operating cash flow | -$35,845 | $312,006 | $359,724 | -$321,378 |
| Free cash flow | — | -$37,231 | $40,237 | -$321,853 |
| Total assets | $4.7M | $4.6M | $3.4M | $2.1M |
| Total liabilities | $5.2M | $5.0M | $3.5M | $3.1M |
| Stockholders' equity | -$534,551 | -$375,543 | -$151,796 | -$951,334 |
| Cash and investments | $3,199 | $37,284 | $23,104 | $6,628 |
| Total debt | $13,173 | $99,618 | $627,526 | $235,275 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Sep 2, 2026 | Sep 2, 2026 |
| 6-K | Current report (foreign issuer) | Jul 27, 2026 | Jul 27, 2026 |
| 6-K | Current report (foreign issuer) | Jun 25, 2026 | Jun 25, 2026 |
| 20-F | Annual report (foreign issuer) | May 15, 2026 | Dec 31, 2025 |
| 6-K | Current report (foreign issuer) | Nov 26, 2025 | Nov 25, 2025 |
| 20-F/A | Amended annual report (foreign issuer) | Sep 23, 2025 | Dec 31, 2023 |
All 38 Cordyceps Sunshine Biotech Holdings Co., Ltd. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.